View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
June 20, 2022

Ultimovacs’ cancer vaccine demonstrates overall survival in Phase I melanoma trial

The 24-month survival rate was reported to be 73% across all 30 subjects in the trial.

Ultimovacs has reported positive two-year data from the ongoing Phase I clinical trial, where its cancer vaccine, UV1, plus pembrolizumab to treat malignant melanoma showed robust overall survival.

A peptide-based vaccine, UV1 elicits a specific T cell response against the universal cancer antigen telomerase.

The company is developing UV1 as an off-the-shelf therapeutic cancer vaccine for usage along with other immunotherapies that need a continued T cell response for their mode of action.

In the trial, 30 patients were treated in two cohorts that only varied in the concentration of GM-CSF used as a vaccine adjuvant.

According to the latest overall survival data following treatment with UV1, the 24-month survival rate was reported to be 73% across all 30 subjects.

Trial subjects will be followed up for long-term survival.

According to data reported in March from the trial, the complete response rate and the objective response rate were found to be 33% and 57%, respectively.

Prior trials with checkpoint inhibitors demonstrated that subjects with clinical responses have enhanced survival rates.

The company plans to report the three-year overall survival data from the first cohort of 20 patients in the fourth quarter of this year.

Ultimovacs CEO Carlos de Sousa said: “This result is the latest in a stream of highly encouraging data that indicate the effectiveness of UV1 in enhancing treatment of malignant melanoma.

“It underlines the potential of UV1 in promoting a concerted immune response in many solid tumour types including those in Ultimovacs’ broader phase II programmes.

“We have seen consistently more positive outcomes from UV1 in combination with pembrolizumab than with the checkpoint inhibitor alone – higher complete response rates, higher overall response rates, higher median progression-free survival and now better 24-month overall survival rates.”

In August last year, the company reported positive top-line data from the second cohort of its Phase I trial of UV1 plus pembrolizumab as a first-line therapy for metastatic malignant melanoma.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena